Mobocertinib – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 55 min read
Mobocertinib - Uses, Dosage, Side Effects, Interaction
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

On this page12 sections

Article Summary

Mobocertinib is an orally available inhibitor of human epidermal growth factor receptor (EGFR) exon 20 insertion mutations, with antineoplastic activity. Mobocertinib is a Kinase Inhibitor. The mechanism of action of mobocertinib is as a HER1 Antagonist and Cytochrome P450 3A Inducer. Upon oral administration, mobocertinib, and its active metabolites, specifically and irreversibly bind to and inhibit exon 20 insertion mutations of EGFR. This prevents EGFR-mediated...

Key Takeaways

  • This article explains Mechanism of Action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.
Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Definition

Mobocertinib is an orally available inhibitor of human epidermal growth factor receptor (EGFR) exon 20 insertion mutations, with antineoplastic activity. Mobocertinib is a Kinase Inhibitor. The mechanism of action of mobocertinib is as a HER1 Antagonist and Cytochrome P450 3A Inducer. Upon oral administration, mobocertinib, and its active metabolites, specifically and irreversibly bind to and inhibit exon 20 insertion mutations of EGFR. This prevents EGFR-mediated signaling and leads to cell death in cells expressing exon 20 insertion mutations. In addition, mobocertinib may inhibit the activity of other EGFR family members, such as human epidermal growth factor receptor 2 (HER2; ERBB2) and HER4. EGFR, HER-2, and -4 are receptor tyrosine kinases often mutated in numerous tumor cell types. They play key roles in tumor cell proliferation and tumor vascularization.

Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the EGFR gene, which are typically associated with a poorer (as compared to “classical” EGFR mutants causing NSCLC) and is associated with resistance to standard targeted EGFR inhibitors. Mobocertinib appears to be an effective means of treating this otherwise NSCLC, exerting an inhibitory effect on EGFR exon 20 insertion mutant variants at concentrations 1.5- to 10-fold lower than those required to inhibit wild-type EGFR. Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic NSCLC in patients with EGFR exon 20 insertion mutations who have failed previous therapies.

Mobocertinib Succinate is the succinate salt form of mobocertinib, an orally available inhibitor of human epidermal growth factor receptor (EGFR) exon 20 insertion mutations, with antineoplastic activity. Upon oral administration, mobocertinib, and its active metabolites, specifically and irreversibly bind to and inhibit exon 20 insertion mutations of EGFR. This prevents EGFR-mediated signaling and leads to cell death in tumor cells expressing exon 20 insertion mutations. In addition, mobocertinib may inhibit the activity of other EGFR family members, such as human epidermal growth factor receptor 2 (HER2; ERBB2) and HER4. EGFR, HER-2, and -4 are receptor tyrosine kinases often mutated in numerous tumor cell types. They play key roles in tumor cell proliferation and tumor vascularization.

Mechanism of Action

The epidermal growth factor receptor (EGFR) is a transmembrane receptor that regulates signaling pathways in the control of cellular proliferation. Mutations in these proteins have been associated with certain types of lung cancer, including non-small cell lung cancer (NSCLC). While the majority of _EGFR_ mutations associated with NSCLC involve the _EGFR_ L858R point mutation or exon 19 deletions (referred to as “classical” _EGFR_ mutations), less common _EGFR_ exon 20 insertion mutations carry a particularly poor prognosis and are associated with resistance to standard targeted EGFR inhibitors. Mobocertinib is an inhibitor of EGFR that irreversibly binds to and inhibits EGFR exon 20 insertion mutations at lower concentrations than wild-type EGFR proteins, exerting a pharmacologic effect on mutant variants at concentrations 1.5- to 10-fold lower than on wild-type proteins.

Mobocertinib is an inhibitor of EGFR that preferentially targets exon 20 insertion mutant variants. It is available as an oral capsule taken with or without food once daily. Mobocertinib can cause a concentration-dependent increase in QTc interval which may lead to life-threatening complications such as Torsades de Pointes. Patients with risk factors for QTc prolongation should consider alternative medications or be monitored carefully throughout therapy. The use of concomitant QTc-prolonging medications should be avoided, as should concomitant inhibitors of CYP3A, as these may increase the concentration of mobocertinib and thus the risk of QTc-prolongation.

Indications

  • Mobocertinib is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based .
  • For the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (as detected by a US FDA-approved test) whose disease has progressed on or after platinum-based chemotherapy
  • Mobocertinib is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.7
  • Locally Advanced Non-Small Cell Lung Cancer
  • Metastatic Non-Small Cell Lung Cancer

Use in Cancer

Mobocertinib succinate is approved to treat:

Mobocertinib succinate is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a benefit to these patients.

Mobocertinib succinate is also being studied in the treatment of other conditions.

Contraindications

  • low amount of magnesium in the blood
  • low amount of calcium in the blood
  • low amount of potassium in the blood
  • torsades de pointes, a type of abnormal heart rhythm
  • prolonged QT interval on EKG
  • abnormal EKG with QT changes from birth
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • lung tissue problem

Strengths: 40 mg

Non-Small Cell Lung Cancer

  • 160 mg orally once a day
  • Duration of therapy: Until or unacceptable toxicity

Dose Adjustments

  • to renal dysfunction (estimated GFR 30 to 89 mL/min/1.73 m2): No adjustment recommended.
  • renal dysfunction (estimated GFR less than 30 mL/min/1.73 m2): Data not available
  • Estimated GFR 30 to 89 mL/min/1.73 m2 by Modification of Diet in Renal Disease equation
  • The recommended dosage has not been established for patients with severe renal dysfunction.

Dose Adjustments

  • Mild or moderate liver dysfunction: No adjustment is recommended.
  • Severe liver dysfunction: Data not available
  • Mild liver dysfunction: Total up to the upper limit of normal (ULN) and AST greater than ULN or total bilirubin greater than 1 to 1.5 times ULN (1 to 1.5 x ULN) and any AST
  • Moderate liver dysfunction: Total bilirubin 1.5 to 3 x ULN and any AST
  • Severe liver dysfunction: Total bilirubin greater than 3 x ULN and any AST
  • The recommended dosage has not been established for patients with severe liver dysfunction.

Dose Adjustments

Dose reduction levels for adverse reactions:

  • First dose reduction: 120 mg orally once a day
  • Second dose reduction: 80 mg orally once a day

QTc Interval Prolongation and Torsades de Pointes

  • Grade 2 (QTc interval 481 to 500 msec):
  • First occurrence: This drug should be withheld until Grade 1 or lower or baseline; upon recovery, this drug should resume at the same dose.
  • : This drug should be withheld until Grade 1 or lower or baseline; upon recovery, this drug should resume at the next lower dose or should be permanently discontinued.
  • Grade 3 (QTc interval at least 501 msec or QTc interval increase of greater than 60 msec from baseline):
  • First occurrence: This drug should be withheld until Grade 1 or lower or baseline; upon recovery, this drug should resume at the next lower dose or should be permanently discontinued.
  • Recurrence: This drug should be permanently discontinued.
  • Grade 4 (torsades de pointes; polymorphic ; signs/symptoms of serious ): This drug should be permanently discontinued.

()/Pneumonitis:

  • Any grade: This drug should be withheld if ILD/pneumonitis is suspected; if ILD/pneumonitis is confirmed, this drug should be permanently discontinued.

Decreased Ejection Fraction or Heart Failure:

  • Grade 2 decreased ejection fraction: This drug should be withheld until Grade 1 or lower or baseline.
  • If recovered to baseline within 2 weeks: This drug should resume at the same dose or the next lower dose.
  • If not recovered to baseline within 2 weeks: This drug should be permanently discontinued.
  • At least Grade 2 heart failure or Grade 3 or 4 decreased ejection fraction: This drug should be permanently discontinued.

:

  • Intolerable or Grade 2 or Grade 3: This drug should be withheld until Grade 1 or lower; this drug should resume at the same dose or the next lower dose.
  • Grade 4:
  • First occurrence: This drug should be withheld until Grade 1 or lower; this drug should resume at the next lower dose.
  • Recurrence: This drug should be permanently discontinued.

Other Adverse Reactions:

  • Intolerable or recurrent Grade 2 or Grade 3: This drug should be withheld until Grade 1 or lower; this drug should resume at the same dose or the next lower dose.
  • Grade 4:
  • First occurrence: This drug should be withheld until Grade 1 or lower.
  • If recovery occurs within 2 weeks: This drug should resume at the next lower dose.
  • If recovery does not occur within 2 weeks: This drug should be permanently discontinued.
  • Recurrence: This drug should be permanently discontinued.
  • Graded per National Cancer Institute Common Terminology Criteria for Adverse Events
  • Coadministration with Moderate CYP450 3A Inhibitors: Concomitant use should be avoided.
  • If coadministration cannot be avoided: The mobocertinib dose should be reduced by about 50% (i.e., from 160 to 80 mg, 120 to 40 mg, or 80 to 40 mg) and QTc interval should be monitored more frequently.
  • After the moderate CYP450 3A inhibitor has been discontinued for 3 to 5 elimination half-lives: Mobocertinib should resume at the dose taken before starting the moderate CYP450 3A inhibitor.

Administration advice:

  • Select patients with locally advanced/metastatic NSCLC for treatment with this drug based on the presence of EGFR exon 20 insertion mutations.
  • For information on US FDA-approved tests: fda.gov/CompanionDiagnostics
  • Administer with or without food, at the same time each day.
  • Swallow capsules whole; do not open, chew, or dissolve the contents of the capsules.
  • If a dose is vomited, do not administer an additional dose; administer the next dose as prescribed the following day.

Side Effects

The Most Common

  • mouth sores
  • decreased appetite
  • rash
  • dry skin or itching
  • red, itchy, or irritated eyes
  • blurry vision
  • hair loss
  • nail infection
  • tiredness
  • muscle or bone pain
  • fatigue
  • runny nose
  • headache
  • diarrhea
  • cough
  • fever
  • shortness of breath
  • chest pain
  • swelling of your ankles and feet

More common

  • Agitation
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • bloody eye
  • blurred vision or blue-green halos seen around objects
  • coma
  • confusion
  • decreased urine output
  • depression
  • diarrhea
  • dizziness
  • dry eyes
  • fainting
  • fast, pounding, or irregular heartbeat or pulse
  • headache
  • hostility
  • irregular heartbeat recurrent
  • irritability
  • lethargy
  • muscle twitching
  • nausea
  • nervousness
  • palpitations
  • pounding in the ears
  • rapid weight gain
  • redness, swelling, and/or itching of the eyelid
  • seizures
  • sensitivity of the eyes to light
  • stupor
  • swelling of the face, ankles, or hands
  • tingling of the hands or feet
  • unusual tiredness or weakness
  • unusual weight gain or loss

Rare

  • Chest pain or discomfort
  • chills
  • cough
  • dilated neck veins
  • fever
  • a general feeling of discomfort or illness
  • irregular breathing
  • swelling of the face, fingers feet, or lower legs
  • thickening of bronchial secretions
  • trouble breathing
  • Acid or sour stomach
  • belching
  • body aches or pain
  • burning, numbness, tingling, or painful sensations
  • cracked lips
  • decreased appetite
  • difficulty in moving
  • ear congestion
  • heartburn
  • indigestion
  • loosening of the fingernails
  • loss or thinning of the hair
  • loss of voice
  • muscle or bone pain
  • pain in the arms or legs
  • rash
  • redness or soreness around the fingernails
  • sneezing
  • sore throat
  • sores, ulcers, or white spots on the lips, tongue, or inside the mouth
  • stomach discomfort, upset, or pain
  • stuffy or runny nose
  • swelling or inflammation of the mouth
  • tender, swollen glands in the neck
  • trouble in swallowing
  • unsteadiness or awkwardness
  • voice changes
  • vomiting
  • weakness in the arms, hands, legs, or fee
  • Redness, swelling, pain of the skin
  • scaling of the skin on the hands and feet
  • ulceration of the skin

Drug interaction

Pregnancy and Lactation

US FDA pregnancy category: Not assigned.

Pregnancy

Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology (12.1)], EXKIVITY can cause fetal harm when administered to a pregnant woman. There are no available data on EXKIVITY use in pregnant women. Oral administration of mobocertinib to pregnant rats during the period of organogenesis resulted in embryolethality (embryo-fetal death) and maternal toxicity at plasma exposures approximately 1.7 times the human exposure based on AUC at the 160 mg once daily clinical dose (see Data). Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage
in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Lactation

There are no data on the presence of mobocertinib or its metabolites in human milk or their effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with EXKIVITY and for 1 week after the last dose.

How should this medicine be used?

Mobocertinib comes as a capsule to take by mouth. It is usually taken once daily with or without food. The length of your treatment depends on how well this medication works for you, and the side effects that you experience. Take mobocertinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take mobocertinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the capsules whole; do not open, chew, crush, or dissolve them.

If you vomit after taking mobocertinib, do not take another dose. Continue your regular dosing schedule.

Your doctor may decrease your dose, or interrupt or discontinue your treatment. This depends on how well the medication works for you and the side effects you experience. Talk to your doctor about how you are feeling during your treatment. Continue to take mobocertinib even if you feel well. Do not stop taking mobocertinib without talking to your doctor. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

What special precautions should I follow?

Before taking mobocertinib,

  • tell your doctor and pharmacist if you are allergic to mobocertinib, any other medications, or any of the ingredients in mobocertinib capsules. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention the medications listed in the IMPORTANT WARNING section and any of the following: angiotensin-converting enzyme (ACE) inhibitors such as benazepril (Lotensin, in Lotrel), captopril, enalapril (Epaned, Vasotec, in Vaseretic), fosinopril, lisinopril (Prinivil, Qbrelis, Zestril, in Zestoretic), moexipril, perindopril, (in Prestalia), quinapril (Accupril, in Accuretic, in Quinaretic), ramipril (Altace), and trandolapril; angiotensin receptor blockers (ARBs) such as azilsartan (Edarbi, in Edarbyclor), candesartan (Atacand, in Atacand HCT), eprosartan (Teveten), irbesartan (Avapro, in Avalide), losartan (Cozaar, in Hyzaar), and valsartan (Diovan, in Diovan HCT, in Exforge, others); diuretics (‘water pills’); efavirenz (Sustiva, in Atripla, in Symfi); hormonal contraceptives (birth control pills, patches, rings, implants, or injections); midazolam; rifampin (Rifadin, Rimactane); and sulfasalazine (Azulfidine). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with mobocertinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
  • tell your doctor if you have or have ever had asthma, emphysema, or other breathing problems (other than lung cancer); or kidney or liver disease.
  • tell your doctor if you are pregnant, plan to become pregnant, or if you plan on fathering a child. If you are female, you will need to take a pregnancy test before you start treatment and use birth control to prevent pregnancy during your treatment and for 1 month after your final dose. Talk to your doctor about which methods you should use; hormonal contraceptives (birth control pills, patches, implants, rings, or injections) may not work well in women who are taking mobocertinib. If you are a male, you and your partner should use birth control during your treatment with mobocertinib and for 7 days after your final dose. If you or your partner become pregnant while taking mobocertinib, call your doctor immediately. Mobocertinib may harm the fetus.
  • tell your doctor if you are breastfeeding. You should not breastfeed while you are taking mobocertinib and for 7 days after the final dose.
  • you should know that mobocertinib often causes diarrhea, which can be severe. Call your doctor if you have diarrhea while taking mobocertinib. Your doctor may tell you to drink plenty of liquids, make changes in your diet, and take medication to control the diarrhea and prevent dehydration (loss of too much water from your body). Call your doctor immediately if you experience any of the following symptoms of dehydration: extreme thirst, dry mouth and/or skin, decreased urination, sunken eyes, or fast heartbeat.

References

  1. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mobocertinib-metastatic-non-small-cell-lung-cancer-egfr-exon-20
  2. https://pubchem.ncbi.nlm.nih.gov/compound/Mobocertinib
  3. https://pubchem.ncbi.nlm.nih.gov/compound/Mobocertinib-succinate
  4. https://go.drugbank.com/drugs/DB16390
  5. https://www.drugs.com/mobocertinib.html
  6. https://medlineplus.gov/druginfo/meds/a621048.html
  7. https://en.wikipedia.org/wiki/Mobocertinib
  8. https://www.webmd.com/drugs/2/drug-182325/mobocertinib-oral/details/list-contraindications
  9. https://www.cancer.gov/about-cancer/treatment/drugs/mobocertinib-succinate
  10. ChEMBL
    http://www.ebi.ac.uk/Information/termsofuse.html
    https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4650319/
  11. IUPHAR/BPS Guide to PHARMACOLOGY
    https://www.guidetopharmacology.org/about.jsp#license
    mobocertinib
    https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10468
    Guide to Pharmacology Target Classification
    https://www.guidetopharmacology.org/targets.jsp
  12. Therapeutic Target Database (TTD)
    Mobocertinib
    http://idrblab.net/ttd/data/drug/details/DI4HA7
  13. ChemIDplus
    LICENSE
    https://www.nlm.nih.gov/copyright.html
    Mobocertinib [USAN]
    https://chem.nlm.nih.gov/chemidplus/sid/1847461431
    ChemIDplus Chemical Information Classification
    https://chem.nlm.nih.gov/chemidplus/
  14. DrugBank
    https://www.drugbank.ca/legal/terms_of_use
    Mobocertinib
    https://www.drugbank.ca/drugs/DB16390
  15. European Chemicals Agency (ECHA)
    https://echa.europa.eu/web/guest/legal-notice
    https://echa.europa.eu/information-on-chemicals
  16. FDA Global Substance Registration System (GSRS)
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    MOBOCERTINIB
    https://gsrs.ncats.nih.gov/ginas/app/beta/substances/39HBQ4A67L
  17. ClinicalTrials.gov
    https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
    https://clinicaltrials.gov/
  18. FDA Pharm Classes
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    MOBOCERTINIB
    https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm
  19. NCI Thesaurus (NCIt)
    https://www.cancer.gov/policies/copyright-reuse
    https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C126752
    NCI Thesaurus Tree
    https://ncit.nci.nih.gov
  20. EU Clinical Trials Register
    https://www.clinicaltrialsregister.eu/
  21. FDA Orange Book
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    Patent:10227342
    https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
  22. National Drug Code (NDC) Directory
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    MOBOCERTINIB
    https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
  23. NCI Cancer Drugs
    LICENSE
    https://www.cancer.gov/policies/copyright-reuse
    Exkivity (Mobocertinib Succinate)
    https://www.cancer.gov/about-cancer/treatment/drugs/mobocertinib-succinate
  24. NLM RxNorm Terminology
    https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
    mobocertinib
    https://rxnav.nlm.nih.gov/id/rxnorm/2570736
  25. Wikidata
    LICENSE
    CCZero
    https://creativecommons.org/publicdomain/zero/1.0/
    Mobocertinib
    https://www.wikidata.org/wiki/Q105338009
  26. PubChem
    https://pubchem.ncbi.nlm.nih.gov
  27. Medical Subject Headings (MeSH)
    https://www.nlm.nih.gov/copyright.html
    mobocertinib
    https://www.ncbi.nlm.nih.gov/mesh/2101757
    MeSH Tree
    http://www.nlm.nih.gov/mesh/meshhome.html
  28. PATENTSCOPE (WIPO)
    SID 395103911
    https://pubchem.ncbi.nlm.nih.gov/substance/395103911

RX Medical Knowledge Graph

Explore this medical topic

Continue through verified related conditions, investigations, medicines, and patient guides. These links are educational and do not replace professional medical advice.

More on this topic

Mobocertinib - Uses, Dosage, Side Effects, Interaction98% relationship confidence

Related medical topics

COVID‑19 Vaccine - Uses, Dosage, Side Effects, Interactions83% relationship confidence Dosage of Filgrastim - Side Effects, Interaction83% relationship confidence Estrogen Drug - Uses, Dosage, Side Effects, Interaction83% relationship confidence Filgrastim - Uses, Dosage, Side Effects, Interaction83% relationship confidence Influenza Vaccines - Uses, Dosage, Side Effect, Interaction83% relationship confidence Lipegfilgrastim - Uses, Dosage, Side Effects, Interaction83% relationship confidence What Is Antacids? -Uses, Dosage, Side Effects, Interaction83% relationship confidence
More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia?, Pain? Associated With Fibromyalgia?, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)
RX Clinical Pathway Engine

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library
  1. Understand the condition Begin with the essential facts and a clear explanation of the topic.
  2. Recognize symptoms Learn common symptoms, signs, and patterns of presentation.
  3. Know when to seek help Review urgent warning signs and when professional assessment may be needed.
  4. Understand causes and risks Explore causes, risk factors, mechanisms, and contributing conditions.
  5. Explore tests and diagnosis Learn how clinicians assess the condition and which investigations may be discussed.
  6. Learn treatment approaches Review general treatment categories and management principles.
  7. Understand medicines safely Continue to medicine education, uses, precautions, and monitoring.
  8. Plan monitoring and follow-up Understand monitoring, complications, rehabilitation, and follow-up learning.
  9. Review prevention and self-care Explore prevention, healthy routines, and questions to discuss with a clinician.

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library
Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician
Tests to discuss with doctor
  • Temperature chart and hydration assessment
  • CBC with platelet count if fever persists or dengue/other infection is possible
  • Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Mobocertinib – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

Internal learning pathway

Explore related RX articles

Related guides from RX Harun are grouped to help readers move from overview to symptoms, tests, treatment, and safe next steps.

Drugs (A - Z)
  1. Vasodilator Drugs Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium…
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine…
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.…
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from…
  5. Imidazole – Uses, Dosage, Side Effects, Interactions DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of…
  6. Carbimazole Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is…